5-(4-Methoxy-benzyl)-pyrimidine-2,4-diamine

ID: ALA19023

Chembl Id: CHEMBL19023

Cas Number: 20285-70-5

PubChem CID: 88462

Max Phase: Preclinical

Molecular Formula: C12H14N4O

Molecular Weight: 230.27

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1ccc(Cc2cnc(N)nc2N)cc1

Standard InChI:  InChI=1S/C12H14N4O/c1-17-10-4-2-8(3-5-10)6-9-7-15-12(14)16-11(9)13/h2-5,7H,6H2,1H3,(H4,13,14,15,16)

Standard InChI Key:  YMGUVTBVYOGUFZ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA19023

   2,4-Diamino-5-(4-methoxybenzyl)pyrimidine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 230.27

Molecular Weight (Monoisotopic): 230.1168

AlogP: 1.24

#Rotatable Bonds: 3

Polar Surface Area: 87.05

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.16

CX LogP: 1.60

CX LogD: 1.41

Aromatic Rings: 2

Heavy Atoms: 17

QED Weighted: 0.83

Np Likeness Score: -0.28

References

1. Dietrich SW, Blaney JM, Reynolds MA, Jow PY, Hansch C..  (1980)  Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines.,  23  (11): [PMID:7005446] [10.1021/jm00185a011]

2. Doweyko AM..  (1988)  The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.,  31  (7): [PMID:3290487] [10.1021/jm00402a025]

3. Selassie CD, Fang ZX, Li RL, Hansch C, Debnath G, Klein TE, Langridge R, Kaufman BT..  (1989)  On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships.,  32  (8): [PMID:2502631] [10.1021/jm00128a035]

4. Coats EA, Genther CS, Selassie CD, Strong CD, Hansch C..  (1985)  Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.,  28  (12): [PMID:3934385] [10.1021/jm00150a026]

5. Coats EA, Genther CS, Selassie CD, Strong CD, Hansch C..  (1985)  Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.,  28  (12): [PMID:3934385] [10.1021/jm00150a026]

6. Roth B, Aig E..  (1987)  2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.,  30  (11): [PMID:3312605] [10.1021/jm00394a012]

7. Loukas YL..  (2001)  Adaptive neuro-fuzzy inference system: an instant and architecture-free predictor for improved QSAR studies.,  44  (17): [PMID:11495588] [10.1021/jm000226c]

8. Crippen GM..  (1997)  Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.,  40  (20): [PMID:9379435] [10.1021/jm970211n]

9. So SS, Richards WG..  (1992)  Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors.,  35  (17): [PMID:1507206] [10.1021/jm00095a016]

10. Ghose AK, Crippen GM..  (1985)  Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.,  28  (3): [PMID:3882967] [10.1021/jm00381a013]

11. Sirichaiwat C, Intaraudom C, Kamchonwongpaisan S, Vanichtanankul J, Thebtaranonth Y, Yuthavong Y..  (2004)  Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.,  47  (2): [PMID:14711307] [10.1021/jm0303352]

12. Li RL, Poe M..  (1988)  Quantitative structure-activity relationships for the inhibition of Escherichia coli dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines.,  31  (2): [PMID:3276891] [10.1021/jm00397a017]

13. Selassie CD, Gan WX, Kallander LS, Klein TE..  (1998)  Quantitative structure-activity relationships of 2, 4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase.,  41  (22): [PMID:9784101] [10.1021/jm970776j]

14. Li R, Hansch C, Kaufman BT..  (1982)  A comparison of the inhibitory action of 5-(substituted-benzyl)-2,4-diaminopyrimidines on dihydrofolate reductase from chicken liver with that from bovine liver.,  25  (4): [PMID:7069722] [10.1021/jm00346a020]

15. Selassie CD, Li R, Hansch C, Khwaja TA, Dias CB..  (1982)  Inhibition by 5-(substituted-benzyl)-2,4-diaminopyrimidines of murine tumor (L5178Y) cell cultures sensitive to and resistant to methotrexate. Further evidence for the sensitivity of resistant cells to hydrophobic drugs.,  25  (5): [PMID:7086836] [10.1021/jm00347a007]

16. Selassie CD, Li RL, Poe M, Hansch C..  (1991)  On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.,  34  (1): [PMID:1899453] [10.1021/jm00105a008]

17. Li RL, Dietrich SW, Hansch C..  (1981)  Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines.,  24  (5): [PMID:7017146] [10.1021/jm00137a012]

18. Selassie CD, Fang ZX, Li RL, Hansch C, Klein T, Langridge R, Kaufman BT..  (1986)  Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.,  29  (5): [PMID:3701780] [10.1021/jm00155a006]

19. Selassie CD, Fang ZX, Li RL, Hansch C, Klein T, Langridge R, Kaufman BT..  (1986)  Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.,  29  (5): [PMID:3701780] [10.1021/jm00155a006]

20. Hansch C, Li R, Blaney JM, Langridge R..  (1982)  Comparison of the inhibition of Escherichia coli and Lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)pyrimidines: quantitative structure-activity relationships, X-ray crystallography, and computer graphics in structure-activity analysis.,  25  (7): [PMID:6809941] [10.1021/jm00349a003]

21. Hopfinger AJ..  (1981)  Inhibition of dihydrofolate reductase: structure-activity correlations of 2,4-diamino-5-benzylpyrimidines based upon molecular shape analysis.,  24  (7): [PMID:7277386] [10.1021/jm00139a010]

22. Ghose AK, Crippen GM..  (1984)  General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors.,  27  (7): [PMID:6737433] [10.1021/jm00373a016]

23. Hopfinger AJ..  (1983)  Theory and application of molecular potential energy fields in molecular shape analysis: a quantitative structure--activity relationship study of 2,4-diamino-5-benzylpyrimidines as dihydrofolate reductase inhibitors.,  26  (7): [PMID:6345782] [10.1021/jm00361a011]

24. Blaney JM, Dietrich SW, Reynolds MA, Hansch C..  (1979)  Quantitative structure-activity relationship of 5-(X-benzyl)-2,4-diaminopyrimidines inhibiting bovine liver dihydrofolate reductase.,  22  (6): [PMID:458817] [10.1021/jm00192a003]

25. Hansch C, Fukunaga JY, Jow PY..  (1977)  Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines.,  20  (1): [PMID:319234] [10.1021/jm00211a020]

Source

Source(1):

• Scientific Literature